We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
- Authors
Mukama, Trasias; Fortner, Renée Turzanski; Katzke, Verena; Hynes, Lucas Cory; Petrera, Agnese; Hauck, Stefanie M.; Johnson, Theron; Schulze, Matthias; Schiborn, Catarina; Rostgaard-Hansen, Agnetha Linn; Tjønneland, Anne; Overvad, Kim; Pérez, María José Sánchez; Crous-Bou, Marta; Chirlaque, María-Dolores; Amiano, Pilar; Ardanaz, Eva; Watts, Eleanor L.; Travis, Ruth C.; Sacerdote, Carlotta
- Abstract
<bold>Background: </bold>CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer.<bold>Methods: </bold>In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer.<bold>Results: </bold>Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9-18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone.<bold>Conclusion: </bold>Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0-9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
- Publication
British Journal of Cancer, 2022, Vol 126, Issue 9, p1301
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/s41416-021-01697-z